Atterocor Lands $16M Series A Round For Cancer Therapy
Ann Arbor, MI-based Atterocor announced Friday that it has raised $16 million in a Series A round led by Frazier, based in Seattle and Menlo Park, CA, and 5am Ventures, based in Waltham, MA and Menlo Park. The funding will go toward developing the company’s adrenal cancer therapy.
Atterocor was founded in 2012 by Julia Owens, Raili Kerppola, and Gary Hammer, who is the director of endocrine oncology at the University of Michigan. Adrenal cancer is rare and patients diagnosed with it often have limited treatment options because it’s discovered late, Owens said in a press release.